Literature DB >> 15015589

Drug-induced caspase-3 activation in a Ewing tumor cell line and primary Ewing tumor cells.

Christine Mauz-Körholz1, Martin Kachel, Britt Harms-Schirra, Anne Klein-Vehne, Peter-Ulrich Tunn, Dieter Körholz.   

Abstract

Ewing sarcoma is a rare malignancy occurring in childhood and adolescence which has a prognosis of about 50% long-term event-free survival, depending on risk factors such as tumor volume, initial metastases at the time of diagnosis and tumor response to presurgical chemotherapy. In order to tailor therapy to the individual patient, new prognostic factors need to be identified. In this study, we showed that etoposide and actinomycin D kill Ewing tumor cells (RD-ES cell line) mainly via a caspase-dependent mechanism. Both drugs induced a significant caspase-3 activation, which can be detected with a new caspase-3 assay. Dose-response analyses showed that induction of cell death and caspase-3 activation is mediated by similar concentration ranges of both drugs. In addition to the cell line, caspase-3 activation was also shown during drug-mediated stimulation of freshly isolated cells from tumor biopsies. In conclusion, actinomycin D and etoposide stimulated caspase-3 activation in a Ewing tumor cell line and in freshly isolated tumor cells, causing drug-induced cell death. Thus, determination of caspase-3 activation might be a suitable method for drug sensitivity testing in patients with Ewing tumors before initiating treatment. This assay could therefore help individualize therapy in future tumor patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15015589

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  A Novel Role of IGF1 in Apo2L/TRAIL-Mediated Apoptosis of Ewing Tumor Cells.

Authors:  Frans van Valen; Henning Harrer; Marc Hotfilder; Uta Dirksen; Thomas Pap; George Gosheger; Hans-Ulrich Humpf; Heribert Jürgens
Journal:  Sarcoma       Date:  2012-10-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.